ARTV Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
26.9M
+10.1%
24.4M
+11.4%
21.9M
-4.2%
22.9M
+0.4%
22.8M
R&D
21.9M
+13.5%
19.3M
+13.6%
17.0M
-3.6%
17.6M
-1.3%
17.9M
SG&A
5.0M
-3.0%
5.1M
+3.6%
4.9M
-6.2%
5.3M
+6.4%
4.9M
Operating Income
-26890000
-10.1%
-24430000
-11.4%
-21932000
+4.2%
-22897000
-0.4%
-22810000
EBITDA
-26198000
-10.2%
-23764000
-11.7%
-21266000
+4.4%
-22235000
-0.3%
-22169000
Net Income
-25005000
-6.3%
-23516000
-13.2%
-20772000
+3.5%
-21528000
-1.3%
-21254000
EPS (Basic)
$-0.63
+33.7%
$-0.95
-11.8%
$-0.85
+3.4%
$-0.88
-1.1%
$-0.87
EPS (Diluted)
$-0.63
+33.7%
$-0.95
-11.8%
$-0.85
+3.4%
$-0.88
-1.1%
$-0.87
Shares (Diluted)
39.4M
+59.7%
24.7M
+0.4%
24.6M
+0.4%
24.5M
+0.4%
24.4M
Artiva Biotherapeutics (ARTV) โ€” Financials